Business
Nuvalent Announces Leadership Promotions
Darlene Noci, A.L.M. promoted to Chief Development Officer Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations CAMBRIDGE, Mass., July
About this update from Nuvalent, Inc.
[{"type":"text","content":"Darlene Noci, A.L.M. promoted to Chief Development Officer\nBenjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations\nCAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two leadership team promotions. Darlene Noci, A.L.M. has been promoted to Chief Development Officer and will continue to oversee all global Product Development and Regulatory Affairs activities. Benjamin Lane, Ph.D. has been promoted to Senior Vice President, Technical Operations and will continue to oversee all Pharmaceutical Development and Quality Assurance activities.\n\n \n \n \n \n \n \n\n \nMs. Noci joined Nuvalent in 2021 as Senior Vice President, Product Development and Regulatory Affairs, bringing over 20 years of experience as an accomplished product development leader specializing in global regulatory affairs and strategic oversight of early and late-stage programs in oncology and rare diseases. At Nuvalent, Ms. Noci has driven the parallel design and execution of global development and regulatory strategies for its two lead programs, NVL-520 and NVL-655, leading to the successful and expedient submission of two INDs and initiation of two ongoing Phase 1/2 studies all within one year. Prior to joining Nuvalent, Ms. Noci held various regulatory, quality assurance and global development team leadership positions with increasing responsibility at X4 Pharmaceuticals, EMD Serono, Infinity, Sanofi, and Genzyme. Throughout her career, Ms. Noci contributed to several successful drug approvals, including Fabrazyme®, Mozobil®, Clolar®, and Bavencio®. Ms. Noci received her Master's in Government from Harvard University.\nDr. Lane joined Nuvalent in 2020 as Vice President, Pharmaceutical Development, bringing over 17 years of experience in process chemistry and the development of pre-clinical through commercial programs at both large and small biotech companies. At Nuvalent, Dr. Lane has built high-performing and integrated pharmaceutical development and quality assurance teams, which have seamlessly delivered clinical supply for two parallel lead programs while navigating the complexities of an evolving global supply-chain. Prior to joining Nuvalent, Dr. Lane ha...